Analysis of the positive rate of 4254 cases of COVID-19 nucleic acid tests in Different Sites in Wuhan, China

Link to article at PubMed

J Med Virol. 2020 Jul 21. doi: 10.1002/jmv.26323. Online ahead of print.

ABSTRACT

BACKGROUND: There's an outbreak of COVID-19 since December 2019, first in Wuhan. It has caused huge medical challenges to Hubei Province with currently more than 67 thousand confirmed cases till March 08, 2020. Identification, there is no clinically effective drug. Isolation and masks are essential to limit human-to-human transmission initially. The nucleic acid test (NAT) of COVID-19 currently was the most reliable established laboratory diagnosis method in clinical.

METHODS: From February 8th, 2020 to March 7th, 2020, 4254 cases were collected for analysis at six nucleic acid collection sites in the community medical team of Hubei Provincial Hospital of Traditional Chinese Medicine, which cover almost all groups who need NAT in Wuhan. Distribution of positive rates in different sites by genders, ages or occupations were compared.

RESULTS: The positive rates of different sites from high to low were: hospital wards (24.71%) > fever clinics (16.57%) > nursing homes (5.51%) > isolation hotels (5.30%) > rehabilitation stations (1.36%) > close contact sites (0.17%). The confirmed patients in isolation hotels, hospital ward and fever clinical were mainly middle-aged and elderly, and most of them were women. The positive rate in isolation hotels and fever clinics gradually decreased over time. There were no significant differences between genders among those six nucleic acid collection sites (P <0.05).

CONCLUSIONS: The hospital wards have the highest positive rate; however, close contact sites have lowest one. Patients who are discharged from hospitals may still have potential risks. Middle-aged and older people remain the focus of epidemic prevention and control. This article is protected by copyright. All rights reserved.

PMID:32691919 | DOI:10.1002/jmv.26323

Leave a Reply

Your email address will not be published.